Effect of estrone sulfate on postmenopausal bone loss

Harry K. Genant, David J. Baylink, J. C. Gallagher, Steven T. Harris, Peter Steiger, Marilyn Herber

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Estrogen replacement therapy confers many beneficial effects to postmenopausal women, such as slowing the rate of bone loss and decreasing the risk of coronary artery disease. This multicenter, placebo-controlled study evaluated the lowest effective daily dose of estrone sulfate (0.3, 0.625, or 1.25 mg) combined with 1000 mg elemental calcium supplementation for preventing bone loss in the immediate postmenopausal period. Spinal bone mineral density was measured using quantitative computed tomography. Compared with baseline, bone mineral density increased significantly (P <.05) after 12 months of 0.625 mg daily (+1.9%) or 1.25 mg daily (+2.5%). The difference between the 0.625-mg and 1.25-mg doses was not statistically significant. Estrone sulfate administration (0.625 and 1.25 mg) produced significant changes in various lipid measurements at both the 6- and 12-month observation points. The prevalence rates for adverse events were comparable among the estrone sulfate groups and the placebo group. Estrone sulfate 0.625 mg daily, combined with 1000 mg elemental calcium supplementation, was the minimum effective dosage to prevent loss of spinal bone mineral density in postmenopausal women over a 12-month period.

Original languageEnglish (US)
Pages (from-to)579-584
Number of pages6
JournalObstetrics and Gynecology
Volume76
Issue number4
StatePublished - Oct 1990

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Genant, H. K., Baylink, D. J., Gallagher, J. C., Harris, S. T., Steiger, P., & Herber, M. (1990). Effect of estrone sulfate on postmenopausal bone loss. Obstetrics and Gynecology, 76(4), 579-584.